Current Press Releases
Arch Biopartners Announces Positive Results of Dose Escalation Human Trial for LSALT Peptide
April 18, 2023 07:10 ET | Source: Arch Biopartners TORONTO, April 18, 2023 (GLOBE NEWSWIRE) -- Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of novel therapeutics targeting organ inflammation, announced that it has safely increased the maximum daily dose of LSALT peptide to 20 mg per day in healthy, normal volunteers in a recently completed human trial in Australia.
LSALT peptide is the Company’s lead drug candidate for treating inflammation in the lungs, liver and ...
Full Release
LSALT peptide is the Company’s lead drug candidate for treating inflammation in the lungs, liver and ...
Full Release
Arch Biopartners Receives Funding for Development of LSALT Peptide Drug Program
March 23, 2023 07:00 ET | Source: Arch Biopartners TORONTO, March 23, 2023 (GLOBE NEWSWIRE) -- Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of novel therapeutics targeting organ inflammation, announced that Arch is receiving advisory services and up to $4,000,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (“NRC IRAP”) to support the research and development of the LSALT peptide (Metablok) program. LSALT peptide is the Company’s lead drug candidate ...
Full Release
Full Release
Arch Scientist Awarded CIHR Grant to Study the Role of Dipeptidase-1 in Chronic Kidney Disease
February 07, 2023 07:05 ET | Source: Arch Biopartners TORONTO, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of innovative technologies and novel therapeutics targeting organ inflammation, announced that an Arch scientist at the University of Calgary was awarded a Canadian Institute of Health Resources (CIHR) Project Grant worth $1,109,250 to further study the role of dipeptidase-1 (DPEP-1) in renal inflammation and chronic kidney disease (CKD). The CIHR grant entitled ...
Full Release
Full Release